NHS Tayside has now considered your request dated 16 May 2019.

NHS Tayside wishes to advise you that there are exemptions applicable to the information requested. Please refer to the exemptions section of this correspondence.

Extract from Request

1. “In your regional NHS board how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?
2. Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS; >RMS, > PPMS and >Not known
3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months? Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:

   - Aubagio (teriflunomide) <5
   - Avonex (interferon beta-1a) 29
   - Betaferon (interferon beta-1b) <5
   - Brabil (glatiramer acetate) 96
   - Copaxone (glatiramer acetate) 148
   - Extavia (beta interferon-1b) 27
   - Gilenia (fingolimod) 64
   - Lemtrada (alemtuzumab) <5
   - Mavenclad (cladribine) 5
   - Ocrevus (Ocrelizumab) <5
   - Plegridy (Peginterferon beta-1a) 15
   - Rebif (beta interferon-1a) 14
   - Tecfidera (dimethyl fumarate) 106
   - Tysabri (natalizumab) 42
   - Zinbryta (daclizumab) 0
   - Ampyra (Fampryra) 0

Clarification (via email 10/06/2019) - “I mean NHS Tayside.”

Response

1. NHS Tayside does not hold the information locally.
2. NHS Tayside does not hold the information locally.
3. Please see response above in black bold.

   Where the values of statistics provided above fall below 5 but are greater than 0, these statistics are represented by ‘<5’. Due to the small numbers of patients involved further detail cannot be provided as disclosure of the information may lead to the identification of individuals.

<table>
<thead>
<tr>
<th>Document Ref.</th>
<th>FOISA Exemption Applied</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGTFOISA6310</td>
<td>Section 17 – Information not held (Q1 &amp; 2).</td>
<td>NHS Tayside does not hold the information locally.</td>
</tr>
<tr>
<td></td>
<td>Section 38 (1)(a) – Personal information (Q3)</td>
<td>Information relating to an individual is personal information. Disclosure of information which would allow the identification of individuals would be in breach of confidentiality and Data Protection principles.</td>
</tr>
</tbody>
</table>
Under section 20 (1) of the Act, if you are dissatisfied with the way NHS Tayside has dealt with your request, you have a right to request a review of our actions and decisions in relation to your request, and you have a right to appeal to the Scottish Information Commission.

A request for an internal review must be made in writing no later than forty working days from receipt of this response and addressed to:

Tayside NHS Board Secretary
Tayside NHS Board Headquarters
Ninewells Hospital & Medical School
Dundee
DD1 9SY

If you are not content with the outcome of the internal review, you have the right to apply directly to the Scottish Information Commissioner for a decision. The Scottish Information Commissioner can be contacted at:

Scottish Information Commissioner
Kinburn Castle
Doubledykes Road
St Andrews
Fife
KY16 9DS

Or via the online appeal service: www.itspublicknowledge.info/Appeal

If you have any queries about this correspondence, please contact:

Information Governance Team
Maryfield House
30 Mains Loan
Dundee
DD4 7BT

Telephone - 01382 424413
E-mail: informationgovernance.tayside@nhs.net

Information Governance
NHS Tayside
17 June 2019

Everyone has the best care experience possible
Headquarters: Ninewells Hospital & Medical School, Dundee, DD1 9SY (for mail) DD2 1UB (for Sat Nav)

Chairman, John Brown CBE
Chief Executive, Grant R Archibald